Curated News
By: NewsRamp Editorial Staff
October 23, 2026
Coherence Neuro Raises $45M to Advance Brain Implant for Cancer
TLDR
- Coherence Neuro's $45M Series A, backed by Founders Fund and OpenAI Startup Fund, positions its SOMA implant to potentially lead the brain cancer treatment market.
- SOMA monitors cancerous cells' electrical signals and emits disruptive signals, working with a wearable and app to track symptoms and treatment history.
- Coherence Neuro's implant could transform glioblastoma prognosis, offering hope to patients with this aggressive cancer and potentially other malignancies.
- Coherence Neuro's button-sized SOMA implant uses electrical signals to disrupt tumor development, a novel approach to fighting brain cancer.
Impact - Why it Matters
This news matters because glioblastoma is one of the most aggressive and lethal forms of brain cancer, with few effective treatment options and a devastating prognosis. Coherence Neuro's implant, SOMA, represents a novel approach that could potentially arrest tumor development by disrupting electrical signals, offering hope where traditional therapies often fall short. The backing from prominent investors like Founders Fund and the OpenAI Startup Fund signals strong confidence in the technology's potential. If successful, this could fundamentally change how cancer is treated, moving beyond drugs and radiation to precise, electrically-based interventions. Moreover, the funding will accelerate clinical trials, bringing the technology closer to patients who desperately need new options. The ripple effects could extend to other malignancies, such as pancreatic cancer, and spur further innovation in the field of bioelectronic medicine.
Summary
Coherence Neuro, a startup developing brain implants to fight cancer, has raised $45 million in a Series A funding round co-led by Peter Thiel’s Founders Fund and the OpenAI Startup Fund. Other participants included Lux Capital, Olive Capital and 8VC. In a post, the company said the funds will enable its first chronic human trial of the implant as a treatment for glioblastoma, seek FDA breakthrough device designation, and expand testing to other conditions such as pancreatic cancer and other malignancies. Coherence is also looking to grow its multi-disciplinary team of operators and builders.
Founded in 2022 by Elise Jenkins and Ben Woodington, Coherence focuses on leveraging technology and neuroscience to change how cancer is treated. Its lead product, SOMA, is a button-sized implant that monitors electrical signals emitted by cancerous cells and delivers electrical signals to disrupt tumor development. The implant works with a removable wearable placed above the ear and an app that tracks symptoms, provides therapy history, and offers real-time patient data. The company is currently testing the implant in glioblastoma, a highly aggressive brain cancer that has affected prominent figures like Senator Ted Kennedy and Senator John McCain. Several consenting patients have had the device implanted during surgery to remove glioblastoma tumors, with initial tests focused on safety. The implant is based on research showing tumors have unique electrical signals and fields; by disrupting this activity, researchers believe cancer development could be arrested before it becomes advanced.
If successful, the implants could change the grim prognosis for glioblastoma patients. As Coherence advances its R&D, other entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also developing novel medications for brain cancers such as glioblastoma. The news was distributed by BioMedWire, a specialized communications platform focused on the latest developments in biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Coherence Neuro Raises $45M to Advance Brain Implant for Cancer
